Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

953P - Trends in disease burden from hepatocellular carcinoma: An observational study of European union 15+ countries

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer Prevention

Tumour Site

Presenters

Georgina Hanbury

Citation

Annals of Oncology (2021) 32 (suppl_5): S818-S828. 10.1016/annonc/annonc677

Authors

G.H. Hanbury1, C.T. Jani2, O. Al Omari2, H. Singh3, J. Shalhoub4, J. Salciccioli5, D. Marshall6

Author affiliations

  • 1 Internal Medicine, Imperial College Healthcare NHS Trust, W2 1NY - London/GB
  • 2 Internal Medicine, Mount Auburn Hospital - Harvard Medical School, 02138 - Cambridge/US
  • 3 Pulmonary And Critical Care, Medical College of wisconsin, milwaukee/US
  • 4 Academic Section Of Vascular Surgery, Department Of Surgery And Cancer, Imperial College London, UK and Imperial Vascular Unit, Imperial College Healthcare NHS Trust,, London/GB
  • 5 Pulmonary And Critical Care, Brigham and Women's Hospital-Harvard Medical School, Boston/US
  • 6 Internal Medicine, National Heart and Lung Institute, Imperial College, London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 953P

Background

Hepatocellular carcinoma is the third leading cause of cancer mortality worldwide. Globally the incidence is increasing with an estimated 900,000 new cases diagnosed in 2020. This study considers the geographical trends in disease burden from hepatocellular carcinoma. Data from 1990 to 2019 is explored to further understand the pattern of disease across EU15+ nations.

Methods

Observational study of The Global Burden of Disease database. Data were for age-standardized incidence rates (ASIR), age-standardized mortality rates (ASMR) and disability-adjusted life years (DALYs) for the years 1990-2019. Mortality to incidence ratios were computed MIR (MIR). Trends were analysed over time and sex-specific absolute and percentage change values were calculated for each country between the start (1991-1993) and the end (2017-2019) of the observation period.

Results

ASIRs increased in 17/19 countries in females and 18/19 countries in males. The greatest increases in ASIR were in Ireland (+149.9%) for females and Portugal (+178.8%) for males. ASMRs increased in all countries except Italy (for both sexes) and Sweden (for females). The largest rises in ASMR were in Australia (+134.8%) for females and Portugal (+159.1%) for males. MIR decreased in all countries except Denmark in males (+8.0) and females (+1.2). Ireland saw the greatest decline in MIR among females (-15.0%) and the United Kingdom for males (-16.4%). DALYs increased in all countries except Italy for both males and females, and Sweden for females.

Conclusions

The incidence of and mortality from hepatocellular carcinoma are increasing in the majority of EU15+ countries. The rise in mortality and fall in MIR suggests that outcomes from hepatocellular carcinoma are improving, despite an increased burden of disease.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.